These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34874514)

  • 1. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
    Blumenfeld AM; Knievel K; Manack Adams A; Severt L; Butler M; Lai H; Dodick DW
    Adv Ther; 2022 Jan; 39(1):692-705. PubMed ID: 34874514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
    Hutchinson S; Silberstein SD; Blumenfeld AM; Lipton RB; Lu K; Yu SY; Severt L
    Cephalalgia; 2021 Aug; 41(9):979-990. PubMed ID: 33874756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials.
    Lipton RB; Singh RBH; Revicki DA; Zhao S; Shewale AR; Lateiner JE; Dodick DW
    J Headache Pain; 2022 Apr; 23(1):50. PubMed ID: 35468729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials.
    Hutchinson S; Dodick DW; Treppendahl C; Bennett NL; Yu SY; Guo H; Trugman JM
    Neurol Ther; 2021 Jun; 10(1):235-249. PubMed ID: 33608814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubrogepant for the Treatment of Migraine.
    Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
    N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
    Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
    Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM
    Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
    Lipton RB; Dodick DW; Ailani J; Lu K; Finnegan M; Szegedi A; Trugman JM
    JAMA; 2019 Nov; 322(19):1887-1898. PubMed ID: 31742631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
    Goadsby PJ; Blumenfeld AM; Lipton RB; Dodick DW; Kalidas K; M Adams A; Jakate A; Liu C; Szegedi A; Trugman JM
    Cephalalgia; 2021 Apr; 41(5):546-560. PubMed ID: 33241721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
    Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
    Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world efficacy, tolerability, and safety of ubrogepant.
    Chiang CC; Arca KN; Dunn RB; Girardo ME; Quillen JK; Dodick DW; Starling AJ
    Headache; 2021 Apr; 61(4):620-627. PubMed ID: 33547676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubrogepant for the treatment of migraine.
    Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
    Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
    CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
    Rizzoli P; Marmura MJ; Robblee J; McVige J; Sacco S; Nahas SJ; Ailani J; De Abreu Ferreira R; Ma J; Smith JH; Dabruzzo B; Ashina M
    J Headache Pain; 2024 Mar; 25(1):35. PubMed ID: 38462625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.
    Zhang Z; Shu Y; Diao Y; Du Y; Chen L; Liu Y; Du B
    Medicine (Baltimore); 2021 Feb; 100(8):e24741. PubMed ID: 33663087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubrogepant to treat migraine.
    Dhir A
    Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
    Nedd M; Garland S; Falk N; Wilk A
    Ann Pharmacother; 2022 Mar; 56(3):346-351. PubMed ID: 34109839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
    Voss T; Lipton RB; Dodick DW; Dupre N; Ge JY; Bachman R; Assaid C; Aurora SK; Michelson D
    Cephalalgia; 2016 Aug; 36(9):887-98. PubMed ID: 27269043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study.
    Manack Adams A; Hutchinson S; Engstrom E; Ayasse ND; Serrano D; Davis L; Sommer K; Contreras-De Lama J; Lipton RB
    J Headache Pain; 2023 Aug; 24(1):102. PubMed ID: 37537578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.